Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.
暂无分享,去创建一个
Emily A. Knapp | Emily A Knapp | L. Saiman | J. Lipuma | B. Marshall | K. Olivier | Elizabeth L Salsgiver | A. Fink
[1] D. Staab,et al. Mental health in cystic fibrosis: turning the tide , 2015, Thorax.
[2] R. Gibson,et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary , 2015, Thorax.
[3] B. Ramsey,et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] M. Rosenfeld,et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. , 2014, Annals of the American Thoracic Society.
[5] J. Adjemian,et al. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. , 2014, American journal of respiratory and critical care medicine.
[6] Emily A. Knapp,et al. Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry , 2014, Annals of Internal Medicine.
[7] L. Saiman,et al. Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update , 2014, Infection Control & Hospital Epidemiology.
[8] M. Jennings,et al. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial , 2014, Trials.
[9] S. McColley,et al. Improved patient safety through reduced airway infection rates in a paediatric cystic fibrosis programme after a quality improvement effort to enhance infection prevention and control measures , 2014, BMJ quality & safety.
[10] L. Saiman,et al. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis , 2014, Pediatric pulmonology.
[11] C. Goss,et al. The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement , 2014, BMJ quality & safety.
[12] Lee H Harrison,et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. , 2013, JAMA internal medicine.
[13] J. Leung,et al. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis , 2013, Current opinion in pulmonary medicine.
[14] P. Vandamme,et al. Burkholderia pseudomultivorans sp. nov., a novel Burkholderia cepacia complex species from human respiratory samples and the rhizosphere. , 2013, Systematic and applied microbiology.
[15] J. Parkhill,et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study , 2013, The Lancet.
[16] N. Høiby,et al. Respiratory bacterial infections in cystic fibrosis , 2013, Current opinion in pulmonary medicine.
[17] C. Goss,et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. , 2012, American journal of respiratory and critical care medicine.
[18] J. Brooke. Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen , 2012, Clinical Microbiology Reviews.
[19] K. E. Bendstrup,et al. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[20] Umer Khan,et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. , 2011, Archives of pediatrics & adolescent medicine.
[21] C. Goss,et al. Review: Staphylococcus aureus and MRSA in cystic fibrosis. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[22] E. Kerem,et al. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. , 2011, American journal of respiratory and critical care medicine.
[23] L. LaVange,et al. Treatment intensity and characteristics of MRSA infection in CF. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[24] R. Thomson. Changing Epidemiology of Pulmonary Nontuberculous Mycobacteria Infections , 2010, Emerging infectious diseases.
[25] P. Dřevínek,et al. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[26] J. Emerson,et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008 , 2010, Pediatric pulmonology.
[27] J. Lipuma. The Changing Microbial Epidemiology in Cystic Fibrosis , 2010, Clinical Microbiology Reviews.
[28] F. Ratjen,et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial , 2009, Thorax.
[29] L. Saiman,et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. , 2009, Chest.
[30] F. Lowy,et al. Staphylococcus aureus Nasal Colonization Among Pediatric Cystic Fibrosis Patients and Their Household Contacts , 2009, The Pediatric infectious disease journal.
[31] S. Leonardi,et al. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients , 2009, European Journal of Clinical Microbiology & Infectious Diseases.
[32] M. Hodson,et al. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[33] S. Boyle-Vavra,et al. Complex molecular epidemiology of methicillin-resistant staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus. , 2008, Chest.
[34] E. Picard,et al. Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel , 2008, Emerging infectious diseases.
[35] P. Berche,et al. Age-Related Prevalence and Distribution of Nontuberculous Mycobacterial Species among Patients with Cystic Fibrosis , 2005, Journal of Clinical Microbiology.
[36] H. Mussaffi,et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy , 2005, European Respiratory Journal.
[37] S. Pitlik,et al. Emergence of Mycobacterium simiae in respiratory specimens , 2005, Scandinavian journal of infectious diseases.
[38] M. Hodson,et al. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients , 2004, European Respiratory Journal.
[39] L. Saiman,et al. Infection Control Recommendations for Patients With Cystic Fibrosis: Microbiology, Important Pathogens, and Infection Control Practices to Prevent Patient-to-Patient Transmission , 2003, Infection Control & Hospital Epidemiology.
[40] P. Hawkey,et al. Molecular Epidemiology of Stenotrophomonas maltophilia Isolated from Clinical Specimens from Patients with Cystic Fibrosis and Associated Environmental Samples , 1998, Journal of Clinical Microbiology.
[41] P. Vandamme,et al. Short Communication Identification and distribution of Achromobacter species in cystic fibrosis , 2013 .